Based on the provided abstracts, the focus is primarily on RHPN1-AS1, a long non-coding RNA antisense to RHPN1, rather than the RHPN1 protein itself. RHPN1-AS1 is a 2030 bp transcript originating from human chromosome 8 that functions as an oncogenic lncRNA across multiple cancer types 1 2. The antisense RNA primarily acts as a competing endogenous RNA (ceRNA), sponging tumor suppressor microRNAs including miR-596, miR-7-5p, and miR-665 to upregulate oncogenic targets 3 4 2. In ovarian cancer, RHPN1-AS1 promotes cell proliferation and metastasis by sequestering miR-596, leading to increased LETM1 expression and activation of the FAK/PI3K/Akt signaling pathway 3. Similarly, in hepatocellular carcinoma, it drives progression via the miR-596/IGF2BP2 axis 5. The lncRNA's stability is enhanced by N6-methyladenosine (m6A) modification mediated by METTL3, contributing to cisplatin resistance in ovarian cancer 6. High RHPN1-AS1 expression is associated with poor prognosis across multiple cancer types. Regarding the RHPN1 protein itself, limited information shows it may serve as a hub gene in breast cancer pathogenesis 7, though detailed functional characterization is lacking in the provided abstracts.